Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
136 hedge funds and large institutions have $1.22B invested in Global Blood Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 50 increasing their positions, 40 reducing their positions, and 19 closing their positions.
235% more call options, than puts
Call options by funds: $14.9M | Put options by funds: $4.43M
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
25% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 40
19% more capital invested
Capital invested by funds: $1.03B → $1.22B (+$195M)
1% more funds holding
Funds holding: 134 → 136 (+2)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$37.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$12.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$9.28M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.58M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$33.1M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$17.3M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$10.8M |
| 4 |
PC
PointState Capital
New York
|
-$7.67M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.63M |
GBT Hedge Fund Activity: Q3 2017 in Review
136 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2017, worth a combined $1.22B — up 19% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new GBT positions and 19 closed out — a net gain of 5 holders — while 50 added to existing stakes and 40 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $37.2M. The largest seller was Citadel Advisors, cutting an estimated $33.1M.
- 136 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2017, up from 134 in Q2 2017.
- Funds reported $1.22B of Global Blood Therapeutics, Inc. stock for Q3 2017, up 19% quarter-over-quarter.
- 24 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2017 and 19 closed out, a net change of +5 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q3 2017 was Point72 Asset Management, an estimated $37.2M added.
- The largest Global Blood Therapeutics, Inc. seller in Q3 2017 was Citadel Advisors, an estimated $33.1M sold.
Based on aggregated 13F filings for Q3 2017.